DLAT：一种新型肝细胞癌预后生物标志物和治疗靶点

Abstract
Figure/Table
References
Related Citation (4)

Download: PDF (10807 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective The aim of this study is to investigate the expression and prognostic value of dihydrolipoamide S-acetyltransferase(DLAT) in hepatocellular carcinoma (HCC), and to provide a new biomarker for prognosis evaluation and drug therapy of HCC. Methods The expression, prognostic value and related biological function of DLAT in HCC were analyzed by bioinformatics. Then, the clinicopathological data of 50 HCC patients from Hunan Provincial People's Hospital were collected. The differential expression of DLAT in tumor tissues and adjacent tissues was analyzed by immunohistochemistry, and the prognostic value of DLAT was further analyzed. HCC cell lines HepG2, Huh-7, SMMC-7721 and human normal liver tissue cell line LO2 were cultured, and the expression of DLAT mRNA in each cell line was detected by q-PCR. HepG2 cells were transfected with si-DLAT (experimental group) and si-NC (control group), and CCK8 assay and flow cytometry were used to detect the effect of DLAT on cell proliferation and apoptosis. Results The expression of DLAT in HCC tissues is higher than that in normal tissues, and expression level of DLAT are positively correlated with poor prognosis. The high expression of DLAT in HCC is closely related to the level of immune cell infiltration and cell cycle regulatory genes. After silencing DLAT, the proliferation of HepG2 cells was significantly slower than that of the control group, and the proportion of apoptosis was higher than that of the control group. Conclusion DLAT can be used as a good prognostic marker for patients with HCC, and may become a new target for the treatment of HCC.

Key words： hepatocellular carcinoma dihydrolipoamide S-acetyltransferase(DLAT) prognostic biomarker

Received: 26 November 2023

PACS:

R735.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Wei
	YANG Jinhui

Cite this article:

CHEN Wei,YANG Jinhui. DLAT: a novel prognostic biomarker and therapeutic target for hepatocellular carcinoma[J]. HuNan ShiFan DaXue XueBao(YiXueBan), 2024, 21(2): 78-85.

URL:

http://yxb.hunnu.edu.cn/EN/ OR http://yxb.hunnu.edu.cn/EN/Y2024/V21/I2/78

[1] TSENG HC, XIONG W, BADETI S, et al.Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma[J]. Nat Commun, 2020, 11(1): 4810.
[2] 张舜柏, 王志强, 张海鸿. CD133对于肝癌患者预后意义的Meta分析[J]. 湖南师范大学学报 (医学版), 2023, 20(02): 130-139.
[3] SGOUROS G, BODEI L, MCDEVITT MR, NEDROW JR.Radiopharmaceutical therapy in cancer: clinical advances and challenges[J]. Nat Rev Drug Discov, 2020, 19(9): 589-608.
[4] PETER TSVETKOV, SHANNON COY, BORYANA PETROVA, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins[J]. Science, 2022, 376(6591): eabq4855.
[5] GOH WQ, OW GS, KUZNETSOV VA, CHONG S, LIM YP.DLAT subunit of the pyruvate dehydrogenase complex is upregulated in gastric cancer-implications in cancer therapy[J]. Am J Transl Res, 2015, 7(6): 1140-51.
[6] BIAN Z, FAN R, XIE L.A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma[J]. Genes (Basel), 2022, 13(5).
[7] FULDA S, GALLUZZI L, KROEMER G.Targeting mitochondria for cancer therapy[J]. Nat Rev Drug Discov, 2010, 9(6): 447-64.
[8] CHEN Q, WANG Y, YANG L, et al.PM2.5 promotes NSCLC carcinogenesis through translationally and transcriptionally activating DLAT-mediated glycolysis reprograming[J]. J Exp Clin Cancer Res, 2022, 41(1): 229.
[9] CHANG L, ZHOU G, SOUFAN O, XIA J. miRNet 2.0: network-based visual analytics for miRNA functional analysis and systems biology[J]. Nucleic Acids Res, 2020, 48(W1): W244-W251.
[10] LI J, MIAO B, WANG S, et al.Hiplot: a comprehensive and easy-to-use web service for boosting publication-ready biomedical data visualization[J]. Brief Bioinform, 2022, 23(4).
[11] XU Y, LI H, et al.Cuprotosis-Related Genes: Predicting Prognosis and Immunotherapy Sensitivity in Pancreatic Cancer Patients[J]. J Oncol, 2022, 2022: 2363043.
[12] WANG S, XING N, MENG X, XIANG L, ZHANG Y.Comprehensive bioinformatics analysis to identify a novel cuproptosis-related prognostic signature and its ceRNA regulatory axis and candidate traditional Chinese medicine active ingredients in lung adenocarcinoma[J]. Front Pharmacol, 2022, 13: 971867.
[13] LOU W, DING B, WANG J, XU Y.The Involvement of the hsa_circ_0088494-miR-876-3p-CTNNB1/CCND1 Axis in Carcinogenesis and Progression of Papillary Thyroid Carcinoma[J]. Front Cell Dev Biol, 2020, 8: 605940.
[14] CHAFOURI-FARD S, SHOOREI H, ANAMAG FT, TAHERI M.The Role of Non-Coding RNAs in Controlling Cell Cycle Related Proteins in Cancer Cells[J]. Front Oncol, 2020, 10: 608975.
[15] RAZAVI ZS, TAJIKNIA V, MAJIDI S, et al.Gynecologic cancers and non-coding RNAs: Epigenetic regulators with emerging roles[J]. Crit Rev Oncol Hematol, 2021, 157: 103192.
[16] FABRIZIO FP, SPARANEO A, MUSCARELLA LA.NRF2 Regulation by Noncoding RNAs in Cancers: The Present Knowledge and the Way Forward[J]. Cancers (Basel), 2020, 12(12).
[17] VALDMANIS PN, KIM HK, CHU K, et al.miR-122 removal in the liver activates imprinted microRNAs and enables more effective microRNA-mediated gene repression[J]. Nat Commun, 2018, 9(1): 5321.
[18] WU G, SUN P, QIN C.GUSBP11 Inhibited The Progression of Triple Negative Breast Cancer via Targeting The miR-579-3p/SPNS2 Axis[J]. Cell J, 2022, 24(5): 230-238.
[19] ZHANG J, LOU W.A Key mRNA-miRNA-lncRNA Competing Endogenous RNA Triple Sub-network Linked to Diagnosis and Prognosis of Hepatocellular Carcinoma[J]. Front Oncol, 2020, 10: 340.
[20] CHEN S, LIU X, PENG C, et al. The phytochemical hyperforin triggers thermogenesis in adipose tissue via a Dlat-AMPK signaling axis to curb obesity[J]. Cell Metab, 2021, 33(3): 565-580. e7.
[21] COLLIGNON E, CANALE A, AL WARDI C, et al. Immunity drives TET1 regulation in cancer through NF-κB[J]. Sci Adv, 2018, 4(6): eaap7309.
[22] 唐乐婷, 曹卜子, 于浩. 基于综合生物信息学对睾丸生殖细胞肿瘤预后相关枢纽基因的筛选及验证. 湖南师范大学学报 (医学版)[J].2022, 19(03): 196-201.
[23] MA L, HERNANDEZ MO, ZHAO Y, et al.Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer[J]. Cancer Cell, 2019, 36(4): 418-430 e416.
[24] UJIIE H, KADOTA K, NITADORI JI, et al.The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers[J]. Oncoimmunology, 2015, 4(6): e1009285.